FLGT icon

Fulgent Genetics

16.46 USD
-0.17
1.02%
At close Feb 21, 4:00 PM EST
After hours
16.57
+0.11
0.67%
1 day
-1.02%
5 days
-3.29%
1 month
-6.64%
3 months
-2.89%
6 months
-29.93%
Year to date
-10.64%
1 year
-32.76%
5 years
-13.37%
10 years
79.30%
 

About: Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Employees: 1,012

0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

4,613% more call options, than puts

Call options by funds: $43.5M | Put options by funds: $924K

38% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 50

25% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 24

1.38% more ownership

Funds ownership: 54.23% [Q3] → 55.61% (+1.38%) [Q4]

1% more funds holding

Funds holding: 182 [Q3] → 184 (+2) [Q4]

12% less capital invested

Capital invested by funds: $357M [Q3] → $314M (-$42.8M) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for FLGT.

Financial journalist opinion

Neutral
Business Wire
2 weeks ago
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 28, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the result.
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
Neutral
Business Wire
2 weeks ago
Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--Foundation Medicine to launch two new hereditary germline tests in the United States through a partnership with Fulgent Genetics.
Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics
Positive
Seeking Alpha
1 month ago
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should Know
The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 31.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should Know
Positive
Zacks Investment Research
3 months ago
All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy
Fulgent Genetics (FLGT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy
Positive
Zacks Investment Research
3 months ago
New Strong Buy Stocks for November 22nd
SNEX, PKG, APAM, MNDY and FLGT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2024.
New Strong Buy Stocks for November 22nd
Neutral
Seeking Alpha
3 months ago
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chairman, Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Li Lu - UBS David Westenberg - Piper Sandler Andrew Cooper - Raymond James Operator Greetings and welcome to the Fulgent Genetics Q3 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
3 months ago
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.39 per share a year ago.
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
Neutral
Business Wire
3 months ago
Fulgent Reports Third Quarter 2024 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Results: Total Revenue of $71.7 million Core Revenue1 grew 9% year-over-year to $71.7 million GAAP loss of $14.6 million, or ($0.48) per share Non-GAAP income of $9.4 million.
Fulgent Reports Third Quarter 2024 Financial Results
Neutral
Business Wire
3 months ago
Fulgent to Participate in Upcoming Conferences
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 12th at 2:45 PM Pacific Time Piper Sandler 36th Annual Healthcare Conference on Wednesday, Decemb.
Fulgent to Participate in Upcoming Conferences
Charts implemented using Lightweight Charts™